In Segment C, members will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or maybe the members are unable to tolerate the study drugs. 88 These preclinical studies present paradigms for potential clinical trials in AML, https://williamp616grc2.wikigdia.com/user